Pfizer-Sales forecasts for 2022 disappoint, the action fell 4% in foreclosure | Photo credits: pio3 / Shutterstock.com
Feb 8 (Reuters) – Pfizer shares are down 4% ahead of the market as it forecast annual sales of $54 billion (47.25 billion euros) for its COVID-19 vaccine and antiviral drug. 19 being below Wall Street expectations.
Pfizer Inc on Tuesday raised its 2022 sales forecast for its COVID-19 vaccine to about $32 billion, and said it expects another $22 billion from sales of Paxlovid, its antiviral pill for the disease. .
Analysts had expected a figure of $33.79 billion for the vaccine and $22.88 billion for Paxlovid, according to Refinitiv data.
Pfizer also said it aims to manufacture more than 4 billion doses of its vaccine in 2022, up from 3 billion in 2021.
Developed with the German company BioNTech and based on messenger RNA technology like that of its competitor Moderna, Pfizer’s anti-COVID vaccine is used in more than 160 countries, including the United States.
The group also plans to produce at least 120 million doses of Paxlovid, deemed effective in reducing the risk of hospitalizations and death in patients at risk of developing a severe form of the disease.
Overall, Pfizer is targeting $98 billion to $102 billion in revenue for 2022, also below the analyst consensus of $105.48 billion. (Report Manas Mishra in Bangalore, French version Diana Mandiá)